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Biomedical Risk Factors of Achilles
Tendinopathy in Physically Active People: a
Systematic Review
Maria Kozlovskaia1,2* , Nicole Vlahovich2, Kevin J. Ashton1 and David C. Hughes2
Abstract
Background: Achilles tendinopathy is the most prevalent tendon disorder in people engaged in running and jumping
sports. Aetiology of Achilles tendinopathy is complex and requires comprehensive research of contributing risk factors.
There is relatively little research focussing on potential biomedical risk factors for Achilles tendinopathy. The purpose of
this systematic review is to identify studies and summarise current knowledge of biomedical risk factors of Achilles
tendinopathy in physically active people.
Methods: Research databases were searched for relevant articles followed by assessment in accordance with PRISMA
statement and standards of Cochrane collaboration. Levels of evidence and quality assessment designation were
implemented in accordance with OCEBM levels of evidence and Newcastle-Ottawa Quality Assessment Scale, respectively.
Results: A systematic review of the literature identified 22 suitable articles. All included studies had moderate level of
evidence (2b) with the Newcastle-Ottawa score varying between 6 and 9. The majority (17) investigated genetic
polymorphisms involved in tendon structure and homeostasis and apoptosis and inflammation pathways.
Overweight as a risk factor of Achilles tendinopathy was described in five included studies that investigated non-genetic
factors. COL5A1 genetic variants were the most extensively studied, particularly in association with genetic variants in the
genes involved in regulation of cell-matrix interaction in tendon and matrix homeostasis. It is important to investigate
connections and pathways whose interactions might be disrupted and therefore alter collagen structure and lead to the
development of pathology. Polymorphisms in genes involved in apoptosis and inflammation, and Achilles tendinopathy
did not show strong association and, however, should be considered for further investigation.
Conclusions: This systematic review suggests that biomedical risk factors are an important consideration in the future
study of propensity to the development of Achilles tendinopathy. The presence of certain medical comorbidities and
genetic markers should be considered when contemplating the aetiology of Achilles tendinopathy. Further elucidation
of biomedical risk factors will aid in the understanding of tendon pathology and patient risk, thereby informing
prevention and management strategies for Achilles tendinopathy.
Trial Registration: PROSPERO CRD42016036558
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Key Points
 Increased BMI and adverse lipid profile may be
important biomarkers of Achilles tendinopathy.
 Further research is required to confirm an association
between genetic variation, of genes encoding collagen
proteins and proteins involved in pathways of tendon
homeostasis and Achilles tendinopathy.
 Genetic risk factors of Achilles tendinopathy may
be modified by geographic factors.
Background
Achilles tendinopathy is one of the most prevalent over-
use tendon injuries associated with physical activities
such as running and jumping [1]. It is the most common
Achilles tendon disorder, with the highest incidence
among runners, track and field athletes and volleyball,
tennis and soccer players [1]. The term ‘tendinopathy’ is
an umbrella term for the description of tendon condi-
tions encompassing pain, swelling and impaired
performance [2, 3]. Achilles tendinopathy can be acute
or chronic. Diagnosis is usually made via a combination
of clinical history, physical examination with or without
medical imaging. The Victorian Institute of Sport
Assessment-Achilles questionnaire (VISA-A question-
naire) may also be used to grade the severity of tendino-
pathy. In the acute phase, the cardinal symptoms are
morning pain and stiffness and pain at the beginning
and end of exercise sessions, with relief in between. The
tendon is diffusely swollen, and there may be palpable
crepitus. Tenderness is maximal 2–6 cm above the
insertion. In chronic tendinopathy, the tendon remains
painful with exercise but the tendon is nodular and
thickened rather than swollen and oedematous [4, 5].
Originally, the pain of Achilles tendinopathy was
attributed to an inflammatory process. While inflamma-
tory cells have been observed, particularly in the early
stages of Achilles tendinopathy, the response does not
seem to be a traditional inflammatory response [6, 7].
Several models have been proposed to explain the
aetiology of Achilles tendinopathy [8–10]. The con-
tinuum model of tendon pathology suggested by Cook
and Purdam consists of three stages: reactive tendinopa-
thy, tendon dysrepair and degenerative tendinopathy [9].
The first stage of the pathology results from acute over-
load of the Achilles tendon and can be characterised as
a non-inflammatory proliferative response in the cell
and matrix. The second stage is described as attempted
tendon healing, through increased production of colla-
gen and proteoglycans. Degenerative tendinopathy is the
third stage and characterised by potentially irreversible
changes in cell and matrix condition such as tenocyte
apoptosis and matrix disorder [11]. Conservative, non-
invasive management is the initial treatment of choice
for Achilles tendinopathy, particularly in the early phases
[4]. Recalcitrance to conservative management is not
uncommon however, and some clinicians argue that
conservative management of chronic Achilles tendinopa-
thy is time consuming and unsatisfactory [5]. Surgery is
sometimes recommended after exhaustion of conserva-
tive treatments, but response rates are variable [5].
Intrinsic and extrinsic aetiological factors interact in
the genesis of Achilles tendinopathy. Intrinsic risk
factors include demographic factors (sex, age, weight
and height) and genetic polymorphisms; and local
anatomical factors include leg length discrepancy, mala-
lignment and decreased flexibility. Extrinsic factors com-
prise therapeutic agents (corticosteroids, antibiotics),
environmental conditions, and physical activity-related
factors, including training patterns, technique and
equipment [1, 2]. The majority of the studies published
over the last two decades are dedicated to the investiga-
tion of anatomical features and biomechanical faults as
possible causes of Achilles tendinopathy. Several reviews
have identified certain anatomic characteristics and
biomechanical and training load errors as risk factors for
Achilles tendinopathy [12–15].
The contribution of biomedical risk factors to the
development of Achilles tendinopathy remains unclear.
These may include medical comorbidities and physio-
logical, biochemical and genetic factors. Imaging and
histopathological analysis of the degenerative and
recovery processes in tendon have provided a better un-
derstanding of the processes associated with tendon
structure and metabolism. In terms of biochemical and
metabolic processes, tendon tissue is relatively inert,
with new collagen synthesis being a slow process [5].
Looking at the genetic coding of proteins comprising
tendon structure may lead to a better understanding of
the underlying molecular processes. Several genetic
association studies have demonstrated that genetic poly-
morphisms influence collagen tissue structure, its turn-
over, degradation processes and therefore susceptibility
to tendon injuries. Medical comorbidities and treatment
of medical conditions also affect tendon structure and
function [16, 17].
There is relatively little research focussing on potential
biomedical risk factors for Achilles tendinopathy. The pur-
pose of this systematic review is to identify studies and
summarise current knowledge of biomedical risk factors of
Achilles tendinopathy in physically active people. This in-
formation will contribute to the understanding of Achilles
tendinopathy and may inform future prevention strategies.
Methods
Literature Search Strategy
This systematic review was registered in the inter-
national prospective register of systematic reviews
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PROSPERO (registration number CRD42016036558).
Systematic review methodology included a thorough
search of all accessible databases of scientific articles.
Keywords were selected by following PICO (Patient,
Intervention, Comparison, Outcome) principle [18].
Four databases (CINAHL, EMBASE, PubMed and
SPORTDiscus) were searched using various combinations
of the keywords: “risk OR predisposition OR genetic* OR
aetiology OR etiology OR overuse OR pathogenesis” AND
“Achilles OR Achilles Tendon” AND “tendinopathy* OR
tendinitis OR tendonitis OR tendinosis OR injury OR
pain” AND “exercise OR physical activity OR sport* OR
run*”. Articles were assessed in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [19] and the stan-
dards of Cochrane collaboration [18]. The search was
completed in August 2016.
Selection Criteria
Selected articles from each database were combined in
one electronic library EndNote (Thomson Reuters, ver-
sion X7). Duplicates were removed automatically in the
electronic library. The titles and abstracts were then
scanned, and clearly irrelevant studies and the remainder
of the duplicates were removed. Following exclusion/in-
clusion criteria, two reviewers examined the abstracts of
the remaining articles and selected studies for the full--
text review. Inclusion criteria were the following: (a)
retrospective and prospective studies, case-control
studies and cohort studies investigating risk factors of
Achilles tendinopathy; (b) clear definition of the studied
injury and medical diagnosis of the injury; and (c) phys-
ically active people as studied subjects. Discrepancies in
the lists of selected articles were resolved through the
discussion between the reviewers.
Quality Assessment
The quality of the included studies was evaluated apply-
ing the Newcastle-Ottawa Quality Assessment Scale
(NOS) for case-control and cohort studies [20]. This
assessment checklist is recommended by the Cochrane
Handbook for Systematic Reviews of Interventions [18, 21].
The NOS checklist assesses quality of the articles in three
domains: selection of the studied groups; comparability of
the groups and control for confounding factors; and expos-
ure for case-control studies or outcome for cohort studies.
Total maximum score is nine for both types of studies.
Results of the studies were critically analysed and presented
in the narrative form reporting odds ratios (OR) and
confidence intervals.
Levels of Evidence
Oxford Centre for Evidence-based Medicine (OCEBM)
levels of evidence was used as a guidance to evaluate
selected articles. Levels of evidence could be identified
according to the type of clinical question [22].
Results Presentation
Results of the studies are described in narrative form,
and odds ratios and confidence intervals or relative risks
of developing Achilles tendinopathy are reported in
Table 2 where possible.
Results
A total of 1631 articles were retrieved after the search of
four databases. Following removal of duplicates, 1185
articles remained. Following screening of titles and
abstracts, reviewers selected 30 articles as potentially
relevant. The final 22 articles were included in the re-
view after full-text screening and discussion between the
reviewers. A flow chart of the article selection is given in
Fig. 1. All included articles were published in English
and had a mixed population of physically active people.
Of the 22 included studies, 17 studies recruited runners
and people who participated in recreational sports such
as squash [23–39]. A single epidemiology study involved
military personnel [40], while one study included elderly
people involved in tennis, jogging and speed walking
[41]. Another study recruited master and veteran
athletes from race walking, long- and middle-distance
running, jumping, hurdles and sprinting [42]. The
remaining two studies recruited physically active people
but did not identify the specific physical activities of the
recruited cohorts [43, 44]. The majority of studies, 17 of
22, used the same definition of Achilles tendinopathy,
assessing clinical diagnostic criteria of symptoms persist-
ing in the Achilles tendon area [26]. One study’s clinical
assessment included VISA-A questionnaire as an assess-
ment tool [42]. Twenty-one out of 22 studies involved
professional medical diagnosis of Achilles tendinopathy
and additionally imaging records’ assessment. The
epidemiology study examined over 80,000 medical re-
cords of military personnel relied on electronic medical
record data [40].
The quality assessment using the NOS tool is pre-
sented in the Table 1. Three studies reached maximum
score of nine [40, 42, 44], and the lowest score was six,
shown in two studies [24, 28]. Studies with the score of
nine included one epidemiologic cohort study of military
personnel and two cross-sectional studies [40, 42, 44].
As the systematic review selection criteria excluded
other systematic reviews, all included studies were
assessed as moderate by the level of evidence (levels 3
and 4) (Table 2).
Discussion
The selected studies focused on a diverse range of bio-
medical risk factors for Achilles tendinopathy such as
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demographic factors, chronic medical conditions, life-
style habits and genetic factors, including those contrib-
uting to collagen structure and tendon homeostasis and
those involved in apoptosis and inflammation. The
majority of the included studies were case-control
studies (Fig. 1). The main limitation of the included
studies was their level of evidence. According to the rec-
ommended OCEBM hierarchy, cohort and case-control
studies approach levels of evidence 3 and 4, with system-
atic reviews and randomised controlled trials providing
levels 1 and 2 evidence [45].This limitation must be
taken into consideration when reviewing the results of
these studies. Here, we discuss the different approaches
undertaken and highlight the main findings obtained
in the search for the key biomedical risk factors for
Achilles tendinopathy.
Non-Genetic Biomedical Risk Factors
Biomedical risk factors include non-modifiable factors
such as age, sex, weight and chronic medical conditions.
A cross-sectional study on 178 master track and field
athletes did not find any association between Achilles
tendinopathy (as determined by VISA-A scores) and age,
sex, weight or height [42]. However, the recruitment
approach used in this study may have resulted in unin-
tentional exclusion of those with the most severe AT as
these athletes may not have been able to compete at the
events where recruitment took place.
A study of 450 cases of Achilles tendinopathy in a
large military personnel cohort showed that overweight
and obesity had a strong association with the develop-
ment of the injury. Additionally, this study found that
moderate alcohol use was associated with increased risk
Fig. 1 PRISMA flowchart of the study selection process
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of Achilles tendinopathy. However, the magnitude of the
OR was modest and could be explained by the possible
influence of alcohol on metabolic and inflammatory fac-
tors [40]. A case-control study of 60 patients with mid-
portion Achilles tendinopathy and 60 matched uninjured
controls by age, sex and body mass index (BMI) showed
that patients with Achilles tendinopathy had higher
levels of triglycerides (TG), lower levels of high-density
lipoprotein cholesterol (HDL-C) and higher TG:HDL-C
ratio. These lipid profiles are typical for insulin resist-
ance syndrome and usually described as dyslipidemia.
This finding suggests that serum lipids may be involved
in the development of Achilles tendinopathy [43, 44]. A
second study investigated fat distribution on male and
female patients with asymptomatic Achilles tendinopa-
thy. Ultrasound examinations of Achilles tendon in 298
participants identified a higher pathology rate among
men than women (17/127, 13%, versus 8/171, 5%). Males
with asymptomatic Achilles tendon pathology had ele-
vated waist:hip ratio, were older and had higher central/
peripheral fat mass and larger waist circumferences
(above 83 cm) compared to individuals without tendon
pathology. This pattern of fat tissue distribution around
the abdominal area is usually associated with metabolic
syndrome and might be linked to the previously re-
ported association between dyslipidemia and Achilles
tendinopathy. Surprisingly, women with asymptomatic
Achilles tendon pathology had lower central:peripheral
fat mass ratios compared to women without pathology,
which could be explained by the effect of oestrogen on
body fat distribution, a factor that was not investigated
in this study [44]. A recent study comparing patients
with Achilles tendinopathy aged over 65 years old to
matching uninjured controls showed significantly higher
prevalence of diabetes, higher BMI and higher level of
sport participation in the injured group [41]. These find-
ings are consistent with other studies which indicate
susceptibility in those with chronic comorbidities. The
types of exercises undertaken by the subjects (speed
walking, jogging and tennis) were relatively high risk in
nature and may have been beyond the loading capacity
of the tendon in ageing individuals [41]. The link be-
tween adverse lipid profile and tendinopathy could be
explained by adipokine modulation of certain enzymes’
production which are important for tenocyte function-
ing. Additionally, chronic low-grade inflammation,
which is typical for obesity, may affect tendon healing
process. At the same time, tendon healing is also
Table 1 The quality of the studies according to the Newcastle-Ottawa Quality Assessment Scale
References Newcastle-Ottawa Quality Assessment Scale (NOS) score Total score
Selection Comparability Exposure/outcome
Abate et al. (2015) [41] 3 2 3 8
Abrahams et al. (2013) [23] 4 1 2 7
Brown et al. (2016) [36] 4 1 2 7
El Khoury et al. (2016) [38] 4 2 2 8
El Khoury et al. (2015) [35] 4 2 2 8
El Khoury et al. (2013) [24] 4 1 1 6
Gaida et al. (2009) [43] 4 2 2 8
Gaida et al. (2010) [44] 4 2 3 9
Gibbon et al. (2016) [37] 4 2 2 8
Hay et al. (2013) [25] 4 1 2 7
Longo et al. (2009) [42] 4 2 3 9
Mokone et al. (2005) [26] 4 2 2 8
Mokone et al. (2006) [27] 4 2 2 8
Nell et al. (2012) [28] 4 0 2 6
Owens et al. (2013) [40] 4 2 3 9
Posthumus et al. (2010) [29] 4 2 2 8
Raleigh (2009) [31] 4 2 2 8
Rickaby et al. (2015) [39] 4 1 2 7
Saunders et al. (2013) [30] 4 2 2 8
September et al. (2008) [34] 4 2 2 8
September et al. (2009) [33] 4 1 2 7
September et al. (2011) [32] 4 1 2 7
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disrupted by low concentrations of immune cells that
tend to migrate into adipose tissue [46]. A systematic
review of 17 articles on the link between lipid profile
and tendon health showed a strong association between
tendon pathology and high lipid parameters [47].
Genetic Contributors to Collagen Structure and Tendon
Homeostasis
Genetic variations are alterations in DNA sequence
among individuals that may account for differences in
phenotype and occasionally in health state. Genetic vari-
ations occurring in more than 1% of a population are
considered useful polymorphisms for genetic linkage
analysis. One of the most commonly investigated types
of genetic variation is the single-nucleotide polymorph-
ism (SNP), a variation in a single nucleotide located at a
specific position in the DNA [48]. The genetic studies
included in this review all employed a candidate gene
approach in order to find genetic polymorphisms in
genes that might influence tendon structure and its de-
velopment and therefore either predispose to or protect
from the development of Achilles tendinopathy. Genetic
predisposition has long been proposed as a contributor
to the development of Achilles tendinopathy. Early
studies assessed the genetic association between ABO
blood type and tendon injuries, described in several in-
vestigations of Finnish and Hungarian patients [49, 50].
However, further research did not support this link, but
identified the chromosomal region of interest on the
long arm of chromosome 9 (9q), which carries genes
closely linked to the ABO blood group gene [27].
This review includes 14 studies investigating 16 genes
linked to collagen structure and tendon homeostasis.
Two of these investigated genes located in 9q region,
particularly tenascin-C (TNC) and COL5A1 [26, 27].
Both studies found an association of polymorphic
variants of TNC and COL5A1 genes with the develop-
ment of Achilles tendinopathy. Tenascin-C regulates
cell-matrix interaction in tendon. TNC contained a
polymorphism in intron 17 where the number of GT di-
nucleotide repeats ranged from 3 to 21, and 95% of the
alleles contained 12 to 17 GT repeats. Those subjects
who were homozygous or heterozygous for the under-
represented alleles of TNC (containing either 13 or 17
GT repeats) were 6.2 times less likely to develop Achilles
tendon injury [26] indicating that these variants of TNC
may be protective from Achilles tendinopathy. COL5A1
encodes the pro-a1 (V) chain of the type V collagen.
Two variants of the COL5A1 gene were associated with
an increased risk of Achilles tendinopathy. In contrast, a
third variant was underrepresented in subjects with
Achilles tendinopathy and therefore was associated with
a reduced likelihood of Achilles tendinopathy develop-
ment [27]. A follow-up study published by the same
research group from South Africa in collaboration with
researchers from Australia replicated previous shown
associations linking COL5A1 gene variants to Achilles
tendinopathy in both Australian and South African
populations [33]. These studies demonstrate the rele-
vance of the TNC and COL5A1 gene polymorphisms in
genetic predisposition to Achilles tendinopathy.
Other studies have assessed the contribution of haplo-
types constructed from candidate polymorphisms, in an
effort to find interactions between genes or gene prod-
ucts. A collaborative study investigated COL27A1 gene
polymorphisms in conjunction with TNC, as COL27A1
is located in the same region of chromosome 9 as the
TNC gene. Type XXVII collagen, encoded by COL27A1,
is responsible for the key structural framework and
tensile strength of the interstitial matrices. Although
there were no significant associations between COL27A1
and Achilles tendinopathy, a GCA haplotype (a set of gen-
etic variants located on a single chromosome) constructed
from one COL27A1 polymorphism (rs946053) and two
TNC polymorphisms (rs13321, rs2104772) showed signifi-
cant association with Achilles tendinopathy [30]. The
study of COL5A1 and MIR608 polymorphisms in South
African and Australian cohorts found that a variant of
COL5A1 contains a putative polymorphic micro-RNA
binding site. The results showed that polymorphisms
rs71746744, rs16399 and rs1134170 in COL5A1 and
polymorphism rs4919510 in MIR608, which encodes a
small micro-RNA, were all independently associated with
Achilles tendinopathy, suggesting a role for these four
variants on messenger ribonucleic acid (mRNA) stability
and the resulting type V collagen synthesis [23]. A follow-
up study of the same polymorphisms in a British cohort
did not find any independent association between studied
COL5A1, MIR608 or IL1β variants and Achilles tendino-
pathy as it was shown in Australian and South African
cohorts [36]. However, an inferred allele combination
constructed from COL5A1 SNPs rs12722, rs3196378 and
rs71746744 was associated with the risk of Achilles
tendon pathology [36].
A further study conducted on South African subjects
analysed polymorphisms in the gene encoding for matrix
metalloproteinase 3 (MMP3) which is involved in the
regulation of extracellular matrix homeostasis. Three of
the investigated polymorphisms (rs679620, rs591058,
rs650108) showed strong association with Achilles tendi-
nopathy, and the most underrepresented haplotype in
patients with Achilles tendinopathy indicated that this
variant was protective against Achilles tendinopathy
[31]. Moreover, since MMP3 genotyping had been done
on the same cohort as COL5A1 reported by September
(2009) [33], this study presented allelic combinations of
MMP3 rs679620 and COL5A1 rs12722, which are asso-
ciated with a lower risk of Achilles tendinopathy. Type V
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collagen is a substrate for MMP3; hence, genetic variants
in COL5A1 and MMP3 genes could account for differ-
ences in the interactions between the proteins [31].
Further investigation of MMP3 gene’s polymorphisms
showed that an inferred haplotype of four SNPs
(rs3025058, rs679620, rs591058 and rs650108) was
associated with Achilles tendinopathy in an Australian
cohort [37].
Polymorphisms in COL12A1 (rs240736, rs970547) and
COL14A1 (rs4870723, rs1563392) were investigated as
they both encode for proteins involved in the biological
processes of fibrillogenesis and, like tenascin C, in the
modulation of the tendon response to mechanical stress
[34]. Additionally, one study of two cohorts from South
Africa and Australia investigated polymorphisms in the
three genes coding for type XI collagen that is homolo-
gous to type V collagen in function and structure [25].
Type XI collagen is usually expressed not only in cartil-
age but also in developing tendons. Several polymor-
phisms (COL11A1 rs3753841 and rs1676486, COL11A2
rs1799907) have been associated with lumbar disc
herniation and rheumatoid arthritis. Whilst none of the
polymorphisms were independently associated with
Achilles tendinopathy, the construction of a pseudoha-
plotype consisting of three polymorphisms and the
COL5A1 polymorphism rs71746744 revealed a signifi-
cant association with Achilles tendinopathy. It is hypoth-
esized that the interaction of genes encoding for type V
and XI collagens could modulate risk of Achilles
tendinopathy, allowing for the possibility that the effects
of type XI collagen variants in the developing tendon
might affect the structural or functional properties of
the mature tendon [25].
Genes involved in tendon homeostasis and particularly
in the extracellular matrix (ECM) have also been investi-
gated for their association with Achilles tendinopathy
risk [24]. The ADAMTS (a disintegrin and metallopro-
teinase with thrombospondin motifs) family of protein-
ases are involved in ECM homeostasis and reported to
be more highly expressed in pathologic than in healthy
tendons. Tissue inhibitor of metalloproteinases (TIMP)
inhibits the actions of MMPs and ADAMTS. Previously
studied cohorts were genotyped for the ADAMTS2
rs1054480, ADAMTS5 rs226794, ADAMTS14 rs4747096,
ADAMTS12 rs3740199 and TIMP2 rs4789932 gene vari-
ants. Researchers found a significant association between
the rs4789932 TIMP2 variant and Achilles tendinopathy.
The balance between TIMPs and MMPs could be a
contributing factor for Achilles tendinopathy development
[24]. The replication of the study of MMP3 and TIMP2
gene variants in a British cohort showed that a gene variant
in TIMP2 rs4789932 was associated with a reduced risk of
Achilles tendon pathology in males [38]. The continued in-
vestigation of proteins involved in the tendon structure
included research of fibrillin and elastin for their role in
elasticity, strength and flexibility of tendons. The polymor-
phisms FBN2 rs331079 and ELN rs2071307 were studied in
Australian and South African cohorts, and the GG
genotype in rs331079 was overrepresented in the group
with Achilles tendinopathy, indicating an association be-
tween fibrillin and injury [35]. Another study conducted on
the same cohorts investigated the contribution of genes
encoding growth factors which play an important role in
tendon growth and homeostasis. TGFB1 and GDF5 (encod-
ing for transforming growth factor-β1 and growth/differen-
tiation factor-5, respectively) were selected as candidates as
these proteins had been shown to increase mechanical
strength after gene transfection in Achilles tendon in
experimentally injured animals [51]. This study showed a
significant association of Achilles tendinopathy with GDF5
rs143383. However, no association with TGFB1 rs1800469
was identified [29].
A thorough analysis of polymorphisms in COL5A1
identified this gene as one of the most likely predispos-
ing factors for Achilles tendinopathy. However, several
studies investigating polymorphisms in genes encoding
for proteins interacting with type V collagen showed that
it is important to be aware of possible connections and
pathways whose interactions might be disrupted and
therefore alter collagen structure and its functionality
and lead to increased or decreased risk of Achilles
tendinopathy.
Genetic Contributors to the Pathways Involved in
Apoptosis and Inflammation
Candidate genes involved in processes surrounding the
development of Achilles tendinopathy, such as tendon
turnover and inflammation, have also been considered
as possible genetic risk factors. The presence of SNPs in
cytokine genes, important contributors to the inflamma-
tory response which have been shown to be upregulated
in tendinopathy and mechanically loaded tendon were
investigated. Interleukin-1β (IL1β) induces inflammatory
mediators that upregulate the expression of proteins in-
volved in degradation of the tendon extracellular matrix
such as MMPs which target type V collagen. The IL1β
receptor antagonist, IL1ra, is encoded by the IL1RN
gene, and its variable number tandem repeat (VNTR)
rs2234663 polymorphism has been previously associated
with gastrointestinal diseases [52], osteoporotic fractures
[53] and atherosclerosis [54]. Whilst genetic variants in
IL1β (rs1143627 and rs16944) have been implicated to
an increase in IL1β gene expression [55], interleukin-6
(IL6) was found to be linked to tenocyte apoptosis,
which is a characteristic of tendinopathy. IL1β and IL6
may also affect COL5A1 gene expression [32]. A SNP in
IL6 (rs1800795) was previously shown to alter IL6 ex-
pression [56] which may lead to increased tenocyte
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apoptosis and therefore potentially increase risk for
Achilles tendinopathy development. In total, the study
investigated four polymorphisms in IL1β, IL1RN and
IL6, although none of these polymorphisms were associ-
ated with the Achilles tendinopathy diagnosis in either
of the South African and Australian population groups
studied. However, inferred allele combinations
constructed from previously studied COL5A1 polymor-
phisms and these IL1β, IL6 and IL1RN VNTR polymor-
phisms were associated with an increased risk of
Achilles tendinopathy in combined groups [32]. This
study concluded that genetic polymorphisms contribut-
ing to the changes in inflammatory pathways may be
important contributors to the risk of Achilles tendinopathy.
Polymorphisms in genes encoding caspases (CASP)
and nitric oxide synthases (NOS) have also been investi-
gated as these molecules had been shown to be involved
in pathways accompanying tendon cell apoptosis, and
their expression has been found to be elevated in tendi-
nopathy [28]. South African and Australian cohorts were
genotyped for four polymorphisms (CASP8 rs3834129,
rs1045485, NOS3 rs1799983 and NOS2 rs2779249). A
significant association between both CASP8 polymor-
phisms (rs3834129, rs1045485) and Achilles tendinopa-
thy was found in both populations. The D/D genotype
of rs3834129 was associated with tendinopathy, whilst
the C allele of rs1045485 was associated with the
absence of Achilles tendinopathy. NOS3 (rs1799983) and
NOS2 (rs2779249) were not associated with Achilles ten-
dinopathy. However, the data presented in this study
showed that the control group in the Australian cohort
was not in Hardy-Weinberg equilibrium (HWE), which
refers to constant proportions of allele and genotype fre-
quencies in a population, and therefore, this association
should be interpreted with caution. Deviations from
HWE in the control group may indicate significant
methodological flaws including selection bias, popula-
tion stratification and genotyping errors [57]. Another
drawback of this study was the conclusion that with an
odds ratio (OR) of 1.67 for the presence of D/D
genotype of rs3834129, the risk of Achilles tendinopathy
was 68% higher in the tendinopathy group than in the
control group [28]. An OR represents the odds that an
outcome will occur given a particular exposure, com-
pared to the odds of the outcome occurring in the
absence of that exposure [58]. Therefore, OR does not
represent the probability of the outcome, and risk as-
sumptions in percentages may not be valid. Overall, this
study was the first that investigated polymorphisms in
caspase pathways.
Tumour necrosis factor receptor 1 gene TNFRSF1A,
which signals inflammation and apoptosis in response to
the tumour necrosis factor-alpha (TNFα), was investi-
gated as a potential gene associated with Achilles
tendinopathy [59]. TNFRSF1A rs4149577 had been associ-
ated with several musculoskeletal and inflammatory dis-
eases; however, this study was the first to investigate this
polymorphism in association with Achilles tendinopathy.
Another polymorphism included in this study was the
caspase-3 gene CASP3 rs1049253, which was shown to
influence CASP3 mRNA expression. Caspase-3 is involved
in cellular apoptosis, including roles in chromatin conden-
sation and DNA fragmentation [60]. This study also inves-
tigated the influence of the copy number variant (CNV)
spanning intron 11-intron 12 in CASP8. CNVs are
segments of DNA greater than 1 kb in size that can influ-
ence phenotypes by changing gene dosage and disruption
of coding sequences in DNA. The results did not show
any significant association between Achilles tendinopathy,
the investigated polymorphisms and CNV. This is possibly
due to the study limitations, such as a relatively small
sample size and a possible additional degree of error due
to the rounding of copy number data into discrete calls,
or may indicate that there is no association between these
CNVs and Achilles tendinopathy [39].
While these studies indicate some links between
polymorphisms in genes involved in apoptosis and
inflammation and Achilles tendinopathy, the majority of
these studies were unable to demonstrate that these
genes are probable risk factors for Achilles tendinopathy.
The processes of apoptosis and inflammation clearly play
a role in the pathology of Achilles tendinopathy;
however, further investigation should be undertaken to
clarify the role of genetic contributors in this patho-
logical processes.
Conclusions
It is clear from previous research that biomechanical is-
sues and training load errors are risk factors for Achilles
tendinopathy [14]. This systematic review suggests that
biomedical risk factors are an important consideration in
the future study of propensity to the development of
Achilles tendinopathy. Increased BMI and adverse lipid
profile were associated with tendinopathy and may be
important biomarkers of tendon pathology. It is evident
that certain genetic markers contribute to the risk profile
of Achilles tendinopathy; however, the demonstrated
associations are currently somewhat ambiguous, and
predictive power has not been demonstrated. Further in-
vestigation is required in this area. In addition, there
appears to be diversity in the genes, dependent on
geographical differences that are significantly associated
with Achilles tendinopathy. This suggests that genetic
risk factors for tendinopathy might be modified by
geographic factors. It is evident that the risk of Achilles
tendinopathy conferred by biomedical factors is complex
and may be a result of the interplay between various
genetic, biochemical and systemic factors which may be
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exacerbated by physical load. Further elucidation of bio-
medical risk factors will aid in the understanding of ten-
don pathology and patient risk, thereby informing
prevention and management strategies for Achilles
tendinopathy.
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